The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Viral Emerging Diseases: Challenges in Developing Vaccination Strategies
Open accessAbstract
In the last decades, a number of infectious viruses have emerged from wildlife or re-emerged, generating serious threats to the global health and to the economy worldwide. Ebola and Marburg hemorrhagic fevers, Lassa fever, Dengue fever, Yellow fever, West Nile fever, Zika, and Chikungunya vector-borne diseases, Swine flu, Severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and the recent Coronavirus disease 2019 (COVID-19) are examples of zoonoses that have spread throughout the globe with such a significant impact on public health that the scientific community has been called for a rapid intervention in preventing and treating emerging infections. Vaccination is probably the most effective tool in helping the immune system to activate protective responses against pathogens, reducing morbidity and mortality, as proven by historical records. Under health emergency conditions, new and alternative approaches in vaccine design and development are imperative for a rapid and massive vaccination coverage, to manage a disease outbreak and curtail the epidemic spread. This review gives an update on the current vaccination strategies for some of the emerging/re-emerging viruses, and discusses challenges and hurdles to overcome for developing efficacious vaccines against future pathogens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1
van Doremalen, N., Bushmaker, T., Morris, D. H., Holbrook, M. G., Gamble, A., Williamson, B. N., Tamin, A., Harcourt, J. L., Thornburg, N. J., Gerber, S. I., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2004973 · Cited by 9,951 · cited 1×
“Indeed, coronaviruses are able to survive on various surfaces for few days but can be inactivated by disinfection (157).”
BackgroundGlobal trends in emerging infectious diseases
Jones, K. E., Patel, N. G., Levy, M. A., Storeygard, A., Balk, D., Gittleman, J. L., & Daszak, P. (2008) · Nature · doi:10.1038/nature06536 · Cited by 8,338
Lai, C.-C., Shih, T.-P., Ko, W.-C., Tang, H.-J., & Hsueh, P.-R. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105924 · Cited by 6,068
Guo (2020) · doi:10.1186/s40779-020-00240-0 · Cited by 4,735 · cited 1×
“The occurrence of significant disease outbreaks—such as SARS (severe acute respiratory syndrome) originating in China in 2002 (8), the 2009 H1N1 swine flu pandemic from Mexico (9), MERS (Middle East respiratory syndrome) that occurred in Saudi Arabia in 2012 (10), the West African outbreak of Ebola virus (EBOV) in lat…”
BackgroundmRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667 · cited 1×
“technological innovations have allowed to overcome some of the concerns associated with instability, half-life, inefficient in vivo delivery, and high innate immunogenicity of mRNA platform (56).”
BackgroundIdentification of a novel coronavirus in patients with severe acute respiratory syndrome
Drosten, C., Günther, S., Preiser, W., van der Werf, S., Brodt, H.-R., Becker, S., Rabenau, H., Panning, M., Kolesnikova, L., Fouchier, R. A. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030747 · Cited by 4,574
Wu, J. T., Leung, K., & Leung, G. M. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30260-9 · Cited by 4,389
Wan, Y., Shang, J., Graham, R., Baric, R. S., & Li, F. (2020) · Journal of Virology · doi:10.1128/jvi.00127-20 · Cited by 4,341 · cited 19×
“This susceptibility enabled the emergence, in approximately two decades, of three new human coronavirus species with epidemic potential: SARS-CoV-1, MERS-CoV, and SARS-CoV-2.”
BackgroundInfluentialSARS and MERS: recent insights into emerging coronaviruses
de Wit, E., van Doremalen, N., Falzarano, D., & Munster, V. J. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.81 · Cited by 3,510
Zika Virus Associated with Microcephaly
Mlakar, J., Korva, M., Tul, N., Popović, M., Poljšak-Prijatelj, M., Mraz, J., Kolenc, M., Resman Rus, K., Vesnaver Vipotnik, T., Fabjan Vodušek, V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1600651 · Cited by 2,884 · cited 1×
“ZIKV During the 2015 outbreak in Brazil, an abnormal microcephaly number and other birth defects in newborns were reported (112).”
Background
Cited by
Antiviral Cyanometabolites—A Review
Mazur-Marzec, H., Cegłowska, M., Konkel, R., & Pyrć, K. (2021) · Biomolecules · doi:10.3390/biom11030474 · Cited by 64
Persistent Joint Pain Following Arthropod Virus Infections
Suchowiecki, K., Reid, S. P., Simon, G. L., Firestein, G. S., & Chang, A. (2021) · Current Rheumatology Reports · doi:10.1007/s11926-021-00987-y · Cited by 37
Strengthening the One Health Approach in the Eastern Mediterranean Region
Hailat, E., Amiri, M., Debnath, N., Rahman, M., Nurul Islam, M., Fatima, Z., Khader, Y., & Al Nsour, M. (2023) · Interactive Journal of Medical Research · doi:10.2196/41190 · Cited by 14
Metadata
- Authors
- Trovato, M., Sartorius, R., D’Apice, L., Manco, R., & De Berardinis, P.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2020-09-03
- Volume
- 11
- Pages
- 2130-2130
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3083287531
- Cited by
- 169
- References
- 29
- FWCI
- 2.54
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Viral Emerging Diseases: Challenges in Developing Vaccination Strategies. https://app.cochat.ai/papers/10.3389/fimmu.2020.02130
- The paper
- Trovato, M., Sartorius, R., D’Apice, L., Manco, R., & De Berardinis, P. (2020). Viral Emerging Diseases: Challenges in Developing Vaccination Strategies. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2020.02130
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.